Patients who have been advised to have adjuvant chemotherapy for colorectal cancer will be enrolled. Patients will be treated with standard doses of capecitabine according to the X-ACT study. Toxicities during cycle one will be graded according to National Cancer Institute Common Toxicity Criteria Version 3.0. Dose reductions during cycle one will be recorded.